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Different effects of phosphatidylinositol 3-kinase
inhibitor LY294002 and Akt inhibitor SH-5 on cell cycle
progression in synchronized HL-60 leukemia cells
Abstract
Background and Purpose: Pharmacological inhibitors of phosphatidy-
linositol 3-kinase (PI3K)/Akt signaling pathway have been proposed in
treatment of leukemia. Our previous studies demonstrated that PI3K in-
hibitor LY294002 and Akt inhibitor SH-5 reduced the number of viable
HL-60 leukemia cells, but exerted different effects on their differentiation.
PI3K inhibitor LY294002 induced an arrest of HL-60 cells in G0/G1 and
G2/M phases of the cell cycle, but the effects of Akt inhibitor on cell cycle
progression have not been investigated. The present study was undertaken in
order to compare the effects of LY294002 and SH-5 on cell cycle progression
in a model of aphidicolin and nocodazole-synchronized HL-60 cells.
Materials and Methods: HL-60 cells were arrested at G1/S phase by
aphidicolin, or G2/M phase by nocodazole, washed and allowed to progress
synchronously through the cell cycle. PI3K inhibitor LY294002 (10 mM)
and Akt inhibitor SH-5 (20 mM) were added to medium after release from
the block. DNA content was determined by propidium iodide staining and
flow cytometry.
Results: In aphidicolin-synchronized HL-60 cells, LY294002 induced a
delay in progression through S and G2/M phases, while Akt inhibitor had no
significant effects. No statistically significant effects were observed in LY294002
or SH-5-treated cells at 1–5 h after release from nocodazole block.
Conclusion: PI3K inhibitor LY294002 and Akt inhibitor SH-5, applied
at doses that effectively inhibit Akt-activity, have different effects on cell cy-
cle progression in aphidicolin-synchronized HL-60 cells, suggesting that
LY294002-induced delay in S and G2/M phase is probably not due to the
specific inhibition of Akt-activity.
INTRODUCTION
Phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway regu-lates many crucial cellular processes, including proliferation, growth,
metabolism, cell motility, survival and hematopoiesis. PI3K family of
lipid kinases is classified into three main classes (PI3KI-III); the class I
is present in different cell types and it is responsible for phosphory-
lation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) into
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3). Upon for-
mation, PtdIns(3,4,5)P3 induces recruitment of protein kinase B (PKB)/
Akt through the phosphoinositide-binding pleckstrin homology (PH)
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tivation of Akt. Once fully activated, Akt phosphorylates
downstream targets that are involved in regulation of cell
growth, proliferation, differentiation and survival (1–3).
As the upregulation of PI3K/Akt pathway has been
found to be a common hallmark of many human tumors,
including acute leukemia (2, 3), it has been proposed
that the selective PI3K/Akt pharmacological inhibitors
might be used in leukemia therapy in combination with
cytotoxic drugs, radiation or all-trans-retinoic acid (ATRA)
(4). Two potent and cell-permeable PI3K-inhibitors have
been widely used to study the role of PI3K in vitro;
wortmannin and LY294002 [2-(4-Morpholinyl)-8-phe-
nyl-4H-1-benzopyran-4-one] (5, 6), and several studies
have demonstrated the antiproliferative effects of LY294002
on leukemia cell lines (7–9). Novel strategies for selective
inhibition of Akt include the development of phospha-
tidylinositol ether lipid analogues (PIA) that cannot be
phosphorylated by PI3K on the 3-position of the myo-
-inositol ring, but bind to the PH domain of Akt, thus
acting as competitive inhibitors for Akt activation (10,
11). Our previous study demonstrated the beneficial ef-
fects of commercially available PIAs, Akt inhibitor I (1L-
-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-
-octadecylcarbonate) and SH-5/Akt inhibitor II (D-3-
-deoxy-2-O-methyl-myo-inositol 1-[(R)-2-methoxy-3-(octa-
decyloxy)propyl hydrogen phosphate]) on HL-60 leuke-
mia cells (9). The presence of Akt inhibitors reduced the
number of both control and ATRA-treated HL-60 cells,
while having no inhibitory effects on ATRA-mediated
differentiation. In contrast, antiproliferative effects of
LY294002 were found to be associated with a reduction
in the percentage of cells with differentiated phenotype.
As the effects of lipid-based inhibitors of Akt on differen-
tiation of leukemia cells differed from the effects of both
LY294002 and down-modulation of Akt by siRNA in the
same cell line, it was suggested that the effects could be
attributed to some other target molecules that are influ-
enced by the pharmacological inhibitor in HL-60 cell
line, but the mechanisms responsible for differences in
the effects of Akt inhibitor and LY294002 were not inves-
tigated.
Although LY294002 is used as an inhibitor of PI3K, it
also inhibits several other enzymes involved in cell cycle
regulation, including ATM/ATR (12) and DNA-PK (13).
Our previous studies demonstrated that antiproliferative
effects of LY294002 on HL-60 cells were associated with
an arrest of cells in G0/G1 and G2/M-phases of the cell cy-
cle, but the effects of Akt inhibitors on HL-60 cell cycle
progression were not investigated (7). The present study
was undertaken in order to compare the effects of
LY294002 and Akt inhibitor II (SH-5) on cell cycle pro-




Fetal bovine serum (FBS), penicillin-streptomycin
and L-glutamine were obtained from Gibco/Invitrogen
(Grand Island, NY, USA). Propidium iodide (PI), RNAse
A, Tris, Igepal, dimethyl sulfoxide (DMSO), aphidicolin
and nocodazole were purchased from Sigma (St Louis,
MO, USA). Aphidicolin and nocodazole were dissolved
in 100% DMSO to a stock concentration of 10 mg/mL
and 200 mg/mL, respectively.
PI3K inhibitor LY294002 and Akt inhibitor II (SH-5)
were obtained from Calbiochem (San Diego, CA, USA).
The inhibitors were dissolved in 100% DMSO to a stock
concentration of 25 mM (LY294002) and 20 mM (Akt in-
hibitor II, SH-5). Other chemicals were of analytical
grade.
Cell culture and cell cycle
synchronization
HL-60 human promyelocytic leukemia cell line
(ECCACC No. 88112501) was purchased from the Eu-
ropean Collection of Animal Cell Cultures, PHLS, Por-
ton, Salisbury, UK. The cells were grown in RPMI 1640
medium supplemented with 10% (v/v) heat-inactivated
FBS, 100 mg/mL streptomycin and 100 units/mL peni-
cillin at 37°C in a humidified 5% CO2 environment. The
cells were passaged twice a week to maintain exponential
growth. The number of viable cells was determined by
using a Bürker-Türk hemocytometer and trypan blue
staining.
In experiments, exponentially growing cells were har-
vested, washed and resuspended in FBS-containing RPMI
medium at the initial cell concentration of 0,25–0,3 ´
106/mL. To induce G1/S arrest, cells were incubated in
the presence of aphidicolin (2 mg/mL) for 18 h, as previ-
ously described (14–16). After the incubation, cells were
released from the block by washing four times with FBS-
-free RPMI medium. To induce an arrest at metaphase,
cells were incubated in the presence of nocodazole (200
ng/mL) for 24 h, as previuosly described (16, 17). After
the incubation, cells were released from the nocodazole
block (time 0) by washing four times in fresh medium, as
described above.
After the block, cells were resuspended in fresh me-
dium containing 10% FBS and incubated further in the
presence of one of the following agents: Akt inhibitor
SH-5 (20 mM), PI3K inhibitor LY294002 (10 mM) or
DMSO vehicle alone (control). At time points indicated,
cells were harvested, stained with propidium iodide and
analyzed by flow cytometry.
Flow cytometric analysis
The anaylsis was performed as previously described
(15–17). Briefly, cells were collected, washed with 2 mL
of ice-cold PBS and stained directly with 300 mL of
propidium iodide solution (10 mM Tris, pH 8.0, 10 mM
NaCl, 10 mg/mL RNAse, 50 mg/mL PI, 0,1% Igepal) for
30 min at 4°C. DNA content was determined using
FACSCalibur system and Cell Quest software (Becton
Dickinson). Aquired events were gated for exclusion of
debris and cell aggregates. DNA analysis was performed
on 15,000 gated events for each sample. ModFit software
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(Becton Dickinson) was used in order to determine the
percentage of cells in the particular phase of cell cycle.
Statistical analysis
The data are presented as means ± S.E.M and evalu-
ated with Student’s t-test for unpaired samples. P< 0,05
was considered as statistically significant.
RESULTS
Incubation of HL-60 cells in the presence of aphi-
dicolin, an inhibitor of DNA polymerase, causes the ma-
jority of cells to arrest at the G1/S boundary. After release
from the block, cells synchronously enter into S phase
and continue to cycle (14–16). To test for the possible ef-
fects of PI3K and Akt inhibitors on the cell cycle progres-
sion through the S phase, HL-60 cells were first treated
with aphidicolin for 18 h, and then released from the
block by washing and resuspending in fresh medium
containing one of the inhibitors or DMSO solvent alone.
PI3K inhibitor LY294002 and Akt inhibitor SH-5 were
applied in doses that were previously shown to be effec-
tive in blocking Akt activation in HL-60 cells (9). At time
indicated, the cells were harvested, stained with PI, and
DNA analysis was performed by FACS. As shown on
Figure 1, control cells that were released from G1/S-block
(time 0) synchronously progressed through the S phase
and reached G2/M phase at 8 h. The presence of Akt in-
hibitor II (20 mM) had no noticeable effects on the cell
cycle progression at the indicated time points. However,
a delay in cell cycle progression was detectable in cells
treated with PI3K inhibitor LY294002 (10 mM), being
most prominent at 6 h after release from aphidicolin
block, which is consistent with the progression delay
through the S phase (Figure 1).
To further investigate the possible effects of PI3K and
Akt inhibitors on progression through G2/M phase, aphi-
dicolin-synchronized cells were analyzed at 10 to 16 h af-
ter release from the block. As shown in Figure 2a and 2b,
the majority of control cells progressed through the G2/M
and returned to G0/G1 phase after 10–12 h. Again, the
cell cycle distribution of HL-60 cells incubated in the
presence of Akt inhibitor did not differ from the distribu-
tion of control cells. In contrast, treatment with LY294002
induced a significant increase in the proportion of cells in
G2/M phase at 10 h after the block (Figure 2b), which
was associated with a decrease in the population of cells
in G0/G1 phase, and an increase in the fraction of cells in
sub-G1 (Figure 2a). However, PI3K inhibitor-treated cells
progressed eventually through the G2/M phase, as de-
tected at 12 and 14 h after the block. A delay in cell cycle
progression was apparent again at 16 h after the block;
while control cells had completed the cycle, passed through
the G1/S checkpoint, and initiated DNA replication, sig-
nificant proportion of LY294002-treated cells had been
delayed in G0/G1, causing a decrease in the percentage of
cells in S phase, as measured by ModFit (Figure 2b).
To further dissect the timing of LY294002-induced
delay in G2/M phase progression in aphidicolin-synchro-
nized HL-60 cells, cells were incubated in the presence
of nocodazole, a microtubule inhibitor that arrests the
cells in metaphase. After release from the block, cells
complete mitosis and go synchronously through G1 pha-
se, thus allowing a study of the events associated with
M/G1 transition and early G1 phase (16). As shown in
Figure 3a, majority of HL-60 cells were arrested in G2/M
phase after incubation in the presence of 200 ng/mL of
nocodazole for 24 h (time 0). After removal of nocoda-
zole by washing and reseeding of cells in the fresh me-
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Figure 1. The effects of PI3K inhibitor LY294002 and Akt inhibitor SH-5 on cell cycle progression of aphidicolin-synchronized HL-60 cells through
the S phase. Cells were incubated in the presence of aphidicolin (2 mg/mL) for 18 h. After release from aphidicolin block by washing and resuspend-
ing the cells into fresh FBS-containing medium, cells were incubated with DMSO solvent alone (control), LY294002 (10 mM) or SH-5 (20 mM),
respectively. Cells were harvested at 0–8 h after release from the aphidicolin arrest, stained with PI solution and DNA content was determined by
FACS.
dium, the percentage of cells in G2/M phase progres-
sively declined, followed by an increase in the proportion
of G0/G1 cells, which indicated the completion of mitosis
and progression through early G1 phase (Figure 3a and
b). No statistically significant differences have been ob-
served in cell cycle distribution of LY294002 or SH-5-
-treated cells in comparison to control cells at 1–5 h after
release from nocodazole block (Figure 3b).
DISCUSSION
An extensive effort has been invested in developing
methods to selectively and efficiently inhibit components
of PI3K/Akt signaling pathways. In 2000, Kozikowski et
al. designed phosphatidylinositol lipid analogues that
target the PH domain of Akt and potently inhibit Akt in
several cell lines, including leukemia cells (10, 18). Re-
sults from our previous study confirmed growth-inhibi-
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b)
a)
Figure 2. The effects of PI3K inhibitor LY294002 and Akt inhibitor SH-5 on cell cycle progression of aphidicolin-synchronized HL-60 cells through
the G2/M phase. After release from the aphidicolin arrest, cells were incubated with DMSO solvent alone (control), LY294002 (10 mM) or SH-5 (20
mM) for 8–16 h. Cells were stained with PI solution and DNA content was determined by flow cytometry. (a) Representative histograms and (b)
ModFit analysis of cell cycle distribution of aphidicolin-synchronized HL-60 cells harvested at 8–16 h after release from G1/S arrest. The values rep-
resent the mean ± SEM from at least three different experiments. * P< 0,05 in comparison to control
tory properties of novel PIA-based inhibitors and sho-
wed a beneficial effect of SH-5 on differentiation of
control and ATRA-differentiated HL-60 cells. When ap-
plied at doses that inhibit Akt activity, LY294002 and Akt
inhibitors exerted the similar growth-inhibitory effects,
but differentiative properties were observed only in PIAs-
-treated HL-60 cells (9). Since then, several observations
suggested that PIAs might have other targets in addition
to Akt, and that identifying »off target« effects could ex-
pand possible clinical applications or help to predict
drug-mediated toxicities (19, 20). In doses that inhibit
Akt, SH-5 and other PIAs have been reported to activate
p38aMAPK (19) and AMP-activated protein kinase (20),
the effects that are missing in LY294002-treated cells. A
recent study, aimed to characterize Akt-independent ef-
fects of the synthetic Akt inhibitors using transcriptomic
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b)
a)
Figure 3. The effects of PI3K inhibitor LY294002 and Akt inhibitor SH-5 on cell cycle progression of nocodazole-synchronized HL-60 cells. Cells
were incubated in the presence of nocodazole (200 ng/mL) for 24 h. After release from the arrest, cells were incubated with DMSO solvent alone
(control), LY294002 (10 mM) or SH-5 (20 mM) for 1–5 h. DNA content was determined by PI staining and FACS analysis. (a) Representative his-
tograms and (b) Mod Fit analysis of cell cycle distribution of nocodazole-synchronized HL-60 cells harvested at 0–5 h after release from metaphase
arrest. The values represent the mean ± SEM from at least three different experiments. * P< 0,05 in comparison to control
profiling and signaling pathway perturbations, demon-
strated that, among other changes, SH-5 and SH-6 down-
-regulate genes associated with the mitotic cell cycle (21).
A decrease in the number of viable HL-60 cells that
was observed 24–48 h after addition of SH-5 or LY294002
could reflect a lower rate of cell cycle progression and/or
increased cell death (9). Our previous study was per-
formed in asynchronous population of HL-60 cells in
which the majority of cells were in G1-phase, so that po-
tential effects that inhibitors might have in the later
stages of the cell cycle might be concealed by the well-de-
scribed role that PI3K/Akt inhibitors have in regulating
progression through G1 and into S-phase (22, 23). The-
refore, the present study was performed in synchronized
HL-60 cells and data obtained showed that the presence
of LY294002 caused a significant delay in progression of
aphidicolin-synchronized cells through multiple points,
including S and G2/M phase. The similar results have
been obtained in double thymidine-blocked HeLa cells
in which the addition of LY294002 (25 mM) immediately
or 5 h after release induced a delay in S and G2 phase, re-
spectively (24). In synchronized NIH3T3 cells, LY294002
caused a delay in S phase exit and G2/M entry, which was
associated with a decrease in the level of cyclin B1 (25).
In addition, a delay in G2/M transition and an increase in
sub-G1 fraction in our model of LY294002-treated cells is
quite similar to the effects of 30 mM LY294002 added to
synchronized HeLa cells 5 h after the block; about 20%
of HeLa cells died by apoptosis while passing through
the G2/M phase (26). Results from the present study also
suggest that the effects of LY294002 on G2/M phase is
probably due to the effect on the cell cycle progression
before cells reach metaphase-anaphase transition, as we
observed no significant effects of the presence of PI3K
inhibitor on the proportion of cells entering G1 phase 1–5
h after release from the nocodazole block. These results
are similar to those obtained in choroidal melanoma cells
synchronized by the presence of nocodazole; the pres-
ence of 20 mM LY294002 had no significant effects on the
cell cycle distribution early (2 h) after nocodazole release,
but caused a well-described G1 arrest 8–20 h after release
from the block (27).
Previous reports concerning the role of Akt in progres-
sion through the G2/M phase are contradictory. First re-
port demonstrated that fibroblasts expressing constitu-
tively active PI3K/Akt forms accumulate in G2/M due to
defective cytokinesis and delayed transition from M to G1
(28). Later studies reported that activated Akt induced a
promotion of mitosis after DNA damage (29, 30). In ad-
dition, suppressing Akt signaling with dominant-nega-
tive Akt was found to repress mitotic entry (25). Even the
time-course of Akt activation during the cell cycle was re-
ported to differ, depending on cell type, as the activity of
Akt was found to increase in the late G2/early M phase in
synchronized HeLa and MDCK cells, while no increase
was recorded in NIH3T3 cells (26). However, other
groups reported an increase in Akt activity to occur dur-
ing G1/S transition and M phase entry in both U2OS and
NIH3T3 cells (31). On the other hand, an increase in the
activity of Akt was found to occur at M/G1 transition in
PC12 cells (32).
Whatever is the role of Akt in progression through the
mitosis, the results of our study show that the presence of
Akt inhibitor SH-5, at a dose that was previously shown
to inhibit an increase in the activity of ATRA-treated
HL-60 cells as effectively as 10 mM LY294002 (9), has no
effects on the progression of the cells well after restriction
point in G1 phase. Differences in the effects of LY294002
and SH-5 on the progression of the cells through S and
G2/M phase of the cycle may be explained by the possibil-
ity that Akt was not the only target of LY294002 that posi-
tively regulates entry into mitosis, and previous studies
showing that inhibitory effects of LY294002 were only
partially reversed in cells transfected by constitutively ac-
tive Akt support the hypothesis (24). Of note is that
LY294002 inhibits not only a wide group of target mole-
cules that are known to be involved in regulation of the
cell cycle, but also blocks the activity of other PI3Ks that
are not related to Akt activity (5). One of the possible tar-
gets includes class II PI3K-C2b that we have previously
shown to be activated in aphidicolin-synchronized cells
8 h after release from the block; the enzyme activity produ-
ced only phosphatidylinositol-3-phosphate (PtdIns(3)P),
which did not activate Akt, but the activation of PI3K -
-C2b was completely inhibited by LY294002 (15).
In conclusion, data from the present study show that
PI3K inhibitor LY294002 and Akt inhibitor SH-5, ap-
plied at doses that effectively inhibit Akt activity, have dif-
ferent effects on cell cycle progression in aphidicolin-
-synchronized HL-60 cells, suggesting that LY294002-in-
duced delay in S and G2/M phase is probably not due to
the specific inhibition of Akt activity.
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